News

BMJ1d
Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke - Annals of the Rheumatic Diseases
Smoking is the most established environmental risk factor for developing rheumatoid arthritis (RA). 1 One hypothesis on the effect of smoking is that smoking causes citrullination of peptides and in ...
BMJ1d
Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study - Annals of the Rheumatic Diseases
Objective Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has ...
BMJ2d
Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis - Annals of the Rheumatic Diseases
Raynaud’s phenomenon (RP) with or without digital ulcer formation is a significant cause of morbidity for patients with systemic sclerosis (SSc, scleroderma). Lichtenstein reported oral sildenafil as ...
BMJ3d
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Objectives To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s ...
BMJ6d
Treating rheumatoid arthritis to target: recommendations of an international task force - Annals of the Rheumatic Diseases
Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).
BMJ9d
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial - Annals of the Rheumatic ...
Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. Methods The GLORIA (Glucocorticoid LOw-dose in ...
BMJ16d
Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study - Annals of the Rheumatic Diseases
Background: Juvenile idiopathic arthritis (JIA) consists of a heterogeneous group of disorders with, for the most part, an unknown immunopathogenesis. Although onset and disease course differ, the ...
BMJ1mon
Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study - Annals of the Rheumatic Diseases
I read with great interest the article by Alpizar-Rodriguez et al regarding the risk of intestinal dysbiosis, particularly Prevotella spp enrichment, in preclinical rheumatoid arthritis (RA).1 Immune ...
BMJ1mon
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of ...
Objectives To inform the 2019 update of the European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA). Methods A systematic literature research (SLR) ...
BMJ1mon
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database - Annals of the Rheumatic Diseases
Objectives To identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD ...
BMJ5mon
Evidence that autoantibody production may be driven by acute Epstein-Barr virus infection in Sjögren’s disease
Objectives Sjögren’s disease (SD) is an autoimmune disease affecting the exocrine glands that is associated with autoantibodies against Ro60/SS-A, anti-Ro52/TRIM21, La/SS-B and others. We examined the ...
BMJ6mon
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a ...
Background Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a ...